|
|
|
| |
|
|
| |
The latest oncology news from News Medical |
|
|
|
| |
 Optimizing Variables for Trial-Ready Liquid Biopsy
Analytes differ dramatically in stability, susceptibility to pre-analytic variation, and compatibility with blood tubes, centrifugation protocols, processing timelines and storage. This talk provides a practical, cross-analyte framework for clinical, translational, and biomarker teams planning liquid biopsy workflows for early trials, late-phase studies, or real-world research.
| |
|
|
| |  | | |  A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing. | | | | |  This review examines how light-responsive bismuth-based nanomaterials could support CT and photoacoustic imaging, antibacterial therapy, and anticancer treatment. By converting light into heat and reactive oxygen species, these experimental nanoplatforms may enable integrated diagnosis and therapy, although clinical translation still requires stronger biosafety, optical performance, and scalability data. | | | | |  A new generation of bispecific antibodies effectively targets cancer cells, minimizing toxicity and enhancing treatment precision in preclinical studies. | | | | |  Researchers at MUSC Hollings Cancer Center have developed a machine learning tool to identify cancer patients who may be at high risk for financial toxicity – the financial stress and hardship that can accompany a cancer diagnosis and treatment. | | | | |  Just two days after his minimally invasive prostate cancer treatment at NYU Langone Health, Broadway performer André De Shields, 80, was back onstage preparing for his next show, Cats: The Jellicle Ball, which debuted in April 2026. | | | | |  A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania... | | | | |  Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell's "powerhouse." | |
|
|
|  | | | How would you rate today's newsletter?
| |
|
|
| | | |
 |
Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now. |
| |
|
|
|
|
|
|
|
